ライフサイエンスコーパス: revaccination

1 sults were randomly allocated to receive BCG revaccination.

2 d with the risk of infection and efficacy of revaccination.

3 nAb] responses), tolerability, and safety of revaccination.

4 s and implementation of adolescent/adult BCG revaccination.

5 n of infection prophylaxis and the timing of revaccination.

6 ne correlates of protection conferred by BCG revaccination.

7 acy of either vaccine would be affected upon revaccination.

8 h IPT modulates BCG immunogenicity following revaccination.

9 ucation, and travel or result in unnecessary revaccination.

10 No safety concerns were raised with IIV-HD revaccination.

11 ty concerns emerged in the context of IIV-HD revaccination.

12 ses, which remained elevated up to 1 y after revaccination.

13 butes of lymphocyte responses boosted by BCG revaccination.

14 memory B cells recognizing that strain upon revaccination.

15 me to revaccination predicted nonresponse to revaccination.

16 n developed protective antibody levels after revaccination.

17 wever, 18 of 19 children seroconverted after revaccination.

18 revaccination and 365 (171,293 children) no revaccination.

19 time, autoantibody levels were boosted upon revaccination.

20 o mount a robust anamnestic Ab response upon revaccination.

21 antibody titers were measured 8 weeks' post revaccination.

22 Nonresponders will not benefit from revaccination.

23 Revaccination 1 year post-dose 1 was well tolerated but

24 andomized to receive initial vaccination and revaccination 12 months later with either placebo or RSV

25 either PN23 primary vaccination (n = 60) or revaccination 3-5 years after receiving a first PN23 vac

26 0(6) colony-forming unit [CFU] doses) or BCG revaccination (5 x 10(5) CFU dose).

27 ount a serological response after 2-dose HAV revaccination (68.4% vs 44.1%, P = .038).

28 Two-dose HAV revaccination administered 4 weeks apart yielded similar

29 nresponders were prospectively recruited for revaccination after HCV eradication.

30 We assessed if revaccination after HCV treatment resulted in improved r

31 ion of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantat

32 rapy (HAART), exposure to measles virus, and revaccination among children infected with human immunod

33 lded similar serological responses as 1-dose revaccination among PWH who were nonresponders or had se

34 schools (176,846 children) were assigned BCG revaccination and 365 (171,293 children) no revaccinatio

35 rategies to improve its efficiency including revaccination and alternate routes of administration.

36 erent after primary vaccination versus after revaccination and indicates that memory can exist in ind

37 rom vaccination is complicated by unreported revaccination and unobserved natural infection or reexpo

38 en seroconverted during the outbreak without revaccination and were likely exposed to wild-type measl

39 be closely monitored and may require earlier revaccination and/or an increased vaccine dose to ensure

40 l, particularly for IgA responses even after revaccination, and the importance of robust humoral resp

41 three adult macaques received an aerosol BCG revaccination approximately 3 years after their initial

42 trategies for immunoglobulin replacement and revaccination are needed.

43 rolled trial to evaluate the efficacy of BCG revaccination, as compared with placebo, for the prevent

44 for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection effic

45 Revaccination at 12 months increased nAb titers, similar

46 and CD3(-)CD56(hi) NK cells at baseline, BCG revaccination boosted these responses, which remained el

47 robust neutralizing antibody responses upon revaccination, but the role CD4(+) T cells play in this

48 We aimed to test the hypothesis that BCG revaccination can enhance responses to unrelated vaccine

49 te reactions occur more frequently following revaccination compared with first vaccination; however,

50 There was no effect of BCG revaccination, compared with no BCG revaccination, on th

51 ined on day 0 (before primary vaccination or revaccination), day 30, day 60, and annually during year

52 Reactogenicity/safety of the revaccination dose were similar to dose 1.

53 We studied revaccination efficacy in two Brazilian cities with tube

54 ded to assess the effect of other factors on revaccination efficacy: time since vaccination, age at v

55 g effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in

56 l cluster of Th17 T(EM) cells induced by BCG revaccination expresses high levels of CD103; these may

57 Although negative results typically prompt revaccination, failure to recognize presumptive immunity

58 ccine nonresponders should be considered for revaccination following HCV cure.

59 influenza and pneumococcal vaccination with revaccination for patients age >65 years who are taking

60 gest that use of a high-dose regimen for HBV revaccination for patients with HIV achieves a higher an

61 Lack of evidence about the effectiveness of revaccination for people 65 years of age or older, when

62 itial nonresponders, 88 (86.3%) responded to revaccination, for an overall response, including to rev

63 cination and safety and immunogenicity after revaccination from this study.

64 Revaccination given to children aged 7-14 years in this

65 Trial participants assigned to the BCG revaccination group received the live parenteral BCG-Rus

66 Data on revaccination in adults are needed.

67 BCG revaccination in QFT-test negative, HIV-negative adolesc

68 the protection against tuberculosis from BCG revaccination in school-aged children who had had one BC

69 fections in this population and the need for revaccination in selected patients to boost their humora

70 We aimed to evaluate the safety of revaccination in these individuals and to interrogate me

71 monitoring of antibody levels and timing of revaccination in these patients.

72 BCG revaccination induced cytokine-positive type 1 helper CD

73 Measles revaccination induced high rates of seroprotection and m

74 By day 30, both primary vaccination and revaccination induced significant increases in opsonic a

75 However, revaccination-induced titer increases were only about 2-

76 he age of 65, has limited effectiveness, and revaccination induces attenuated antibody responses.

77 oring is needed to determine the optimal RSV revaccination interval.

78 We found no evidence that BCG revaccination is an effective strategy to improve immuno

79 ation at 6 months of age followed by routine revaccination is recommended when exposure of infants to

80 range in prevention-of-disease efficacy, BCG revaccination may have a positive health impact and be c

81 Revaccination may renew protection.

82 onstrated that Bacille Calmette-Guerin (BCG) revaccination of adolescents reduced the risk of sustain

83 Revaccination of adults >=50 years with mRNA-1345 was we

84 ble to diphtheria (e.g., adults) rather than revaccination of children.

85 Revaccination of CRM-OS recipients with PS at 2 months d

86 The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 o

87 Revaccination of healthy adults with pneumococcal polysa

88 Timely revaccination of HIV-1-infected nonresponders increased

89 Our findings support revaccination of individuals who report sARs to COVID-19

90 These findings suggest that revaccination of individuals with an immediate allergic

91 This study shows that revaccination of low-responding HCWs with the pH1N1 vacc

92 Revaccination of older adults with PN23 was comparable t

93 vaccine policy, including the possibility of revaccination of older adults.

94 Gs and to ensure consistent product release, revaccination of plasma donors was investigated as a mea

95 majority of these cases being preventable by revaccination of previously vaccinated persons.

96 ation, for an overall response, including to revaccination, of 94.9%.

97 ted to characterize the effects of HAART and revaccination on measles immunoglobulin G (IgG) serostat

98 e effects of BCG revaccination versus no BCG revaccination on the immunogenicity of subsequent unrela

99 t of BCG revaccination, compared with no BCG revaccination, on the response observed for any vaccine.

100 his result might be confounded by unrecorded revaccination or natural infection with wild yellow feve

101 erize in-depth the cellular responses to BCG revaccination or to a H4:IC31 vaccine boost to identify

102 y vs. postnatal delivery) and the benefit of revaccination over the course of multiple pregnancies.

103 ion against smallpox during the postexposure revaccination period may require T cell memory as an ess

104 Some vaccination and revaccination plans for patients with cancer may be affe

105 ldren with ALL would benefit from systematic revaccination postchemotherapy.

106 plasma HIV-1 RNA levels, and longer time to revaccination predicted nonresponse to revaccination.

107 evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculo

108 BCG vaccination is routine in Brazil but BCG revaccination procedures vary by state.

109 ese data remain relevant considering ongoing revaccination programs.

110 uring years 2-5 after primary vaccination or revaccination remained higher than in vaccine-naive pers

111 piratory syndrome coronavirus 2 (SARS-CoV-2) revaccination requires immunogenicity and safety data fo

112 The 2-dose revaccination schedule generated significantly higher an

113 ccine-associated adverse events, the 10-year revaccination schedule has come into question.

114 Revaccination status was masked during linkage and valid

115 ty to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.

116 effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.

117 successful primary vaccination, the optimal revaccination strategy remains unclear.

118 work supports development of MTBVAC use as a revaccination strategy to improve on the effects of BCG

119 ody levels tended to be modestly lower after revaccination, study groups had similar GMCs at later ti

120 concentrations (GMCs) of IgG were higher in revaccination than primary vaccination subjects.

121 Ten days after revaccination, the conjugate and IPV groups had similar

122 tudy assessed safety and immunogenicity of a revaccination (third) dose of the 120 mug RSVPreF3-AS01E

123 One week following revaccination, those given 2 doses of PsA-TT had the gre

124 Before revaccination, titers were higher in the conjugate and M

125 Revaccination transiently boosted BCG-specific Th1 cytok

126 BCG revaccination transiently expanded peripheral blood freq

127 However, recent encouraging data from BCG revaccination trials in adults combined with studies on

128 4(+) T cell subpopulations (T(EM)) after BCG revaccination, two of which are highly polyfunctional.

129 rivalent inactivated influenza vaccine, with revaccination up to 3 seasons.

130 ntrolled trial to compare the effects of BCG revaccination versus no BCG revaccination on the immunog

131 GMFRs 1 month after revaccination vs levels before revaccination were 1.4 to

132 on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination).

133 y over 2 seasons of a first dose followed by revaccination was 67.1% (97.5% CI: 48.1-80.0%) against R

134 The efficacy of BCG revaccination was 9% (-16 to 29%).

135 In secondary analyses BCG revaccination was associated with higher COVID-19 incide

136 RSVpreF revaccination was immunogenic and well tolerated among a

137 phase 2 trial, bacille Calmette-Guerin (BCG) revaccination was not shown to provide protection from p

138 1 month after revaccination vs levels before revaccination were 1.4 to 2.3 and 1.4 to 2.2 for 18- to

139 ow-up history, and no record of yellow fever revaccination were included; children seropositive for y

140 Peak GMTs after revaccination were lower than those after initial vaccin

141 y, neutralizing antibody responses following revaccination were significantly higher in individuals w

142 serological response rates at week 48 after revaccination were similar between the 2 groups (2- vs 1

143 GMTs 12 months after initial vaccination and revaccination were similar, with GMFRs ranging from 0.7

144 Day 30 levels following revaccination were slightly lower but not significantly

145 Revaccination with 120 mug RSVPreF3-AS01E 18 months afte

146 We compared revaccination with 23-valent pneumococcal polysaccharide

147 els for 5 years after primary vaccination or revaccination with 23-valent pneumococcal polysaccharide

148 This open-label, phase 3 trial evaluated revaccination with 50-ug mRNA-1345 administered 12 month

149 Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine

150 e of HIV-1-infected initial nonresponders to revaccination with a standard HBV vaccine series.

151 sults of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guerin (BCG) agains

152 of isoniazid preventive therapy (IPT) before revaccination with bacillus Calmette-Guerin (BCG) in hea

153 pact of infant BCG vaccination on subsequent revaccination with BCG, a pilot study of three adult mac

154 exposure tuberculosis vaccination, including revaccination with BCG, might benefit Mtb-uninfected HCW

155 studies of the possible association between revaccination with live attenuated vaccines and off-targ

156 It has been hypothesized that revaccination with live vaccines is associated with redu

157 In this study, revaccination with MMR appeared safe in relation to off-

158 cal trial, we compared the immunogenicity of revaccination with PCV ( n = 131) or PPV (n = 73) among

159 Among persons with HIV infection, revaccination with PCV was only transiently more immunog

160 Both primary vaccination and revaccination with PN23 induce antibody responses that p

161 Primary vaccination or revaccination with PN23 induced significant increases in

162 Based on our results, revaccination with pneumococcal vaccines after transplan

163 isk does not represent a contraindication to revaccination with PPV for recommended groups.

164 disease persists, and antibody responses to revaccination with the 23-valent polysaccharide vaccine

165 We determined whether revaccination with the 7-valent pneumococcal conjugate v

166 We examined if revaccination with the live measles, mumps, and rubella

167 Revaccination with the pH1N1 vaccine elicited rapid HI a

168 of an antigen to allow antibody responses on revaccination) with vaccine directed toward an older avi

169 mained high and few became carriers, booster revaccination within 10 years seems unnecessary.

170 vation in smallpox outbreaks that successful revaccination within 4 days of exposure is partially pro

171 ed reactions, change of vaccine platform, or revaccination without vaccine/excipient ST were excluded